Search Results - Mehta-Damani, A

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    An analysis of variability in the manufacturing of dexosomes: Implications for development of an autologous therapy

    An analysis of variability in the manufacturing of dexosomes: Implications for development of an autologous therapy by Patel, Sanjay, Mehta-Damani, Anita, Shu, Helen, Le Pecq, Jean-Bernard

    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    Cellular and molecular basis of human gamma delta T cell activation. Role of accessory molecules in alloactivation

    Cellular and molecular basis of human gamma delta T cell activation. Role of accessory molecules in alloactivation by Takamizawa, M, Fagnoni, F, Mehta-Damani, A, Rivas, A, Engleman, E G

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  3. 3
    IL-2 based cancer immunotherapies: an evolving paradigm

    IL-2 based cancer immunotherapies: an evolving paradigm by Rokade, Sushama, Damani, Anita Mehta, Oft, Martin, Emmerich, Jan

    Get full text
    Items that this one cites
    Article
    Save to List
    Saved in:
  4. 4
    The Evolution of Single-Cell Analysis and Utility in Drug Development

    The Evolution of Single-Cell Analysis and Utility in Drug Development by Mitra-Kaushik, Shibani, Mehta-Damani, Anita, Stewart, Jennifer J., Green, Cherie, Litwin, Virginia, Gonneau, Christèle

    Published in The AAPS journal
    Get full text
    Items that this one cites
    Items that cite this one
    Article
    Save to List
    Saved in:
  5. 5
    A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or Refractory CD19 Expressing Hematologic Malignancies (NCT05665062)

    A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or... by Palomba, Maria Lia, Caimi, Paolo F., Mei, Matthew, Hernandez-Ilizaliturri, Francisco, Shouse, Geoffrey, Winter, Allison M., Yedinak, Greg, Mou, David, Huang, Nestor, Moua, Anna, Oft, Martin, Aspuria, Paul-Joseph, Mehta-Damani, Anita, Rizvi, Naiyer, Unabia, Sherry, Taylor, Peg, McLeroy, Jeffrey, Cortese, Matthew J

    Published in Blood
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Abstract CT125: A Phase 1 study to evaluate the safety and tolerability of a combination autologous CD19 CAR T cell therapy (SYNCAR-001) and orthogonal IL-2 (STK-009) in subjects with relapsed or refractory  CD19 expressing hematologic malignancies (NCT05665062)

    Abstract CT125: A Phase 1 study to evaluate the safety and tolerability of a combination autologous CD19 CAR T cell therapy (SYNCAR-001) and orthogonal IL-2 (STK-009) in subjects w... by Palomba, Maria Lia, Mei, Matthew G., Caimi, Paolo F., Cortese, Matthew, Davila, Marco, Yadnik, Greg, Huang, Nestor, Mou, David, Oft, Martin, Aspuria, Paul-Joseph, Mehta-Damani, Anita, Ratti, Navneet, Rizvi, Naiyer, Azrilevich, Alex, Reshef, Ran

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  7. 7
    Abstract 1801: STK-012, an a/b-selective IL-2 activates tumor antigen specific CD25+ CD8 T cells to reject tumors without acute vascular toxicity

    Abstract 1801: STK-012, an a/b-selective IL-2 activates tumor antigen specific CD25+ CD8 T cells to reject tumors without acute vascular toxicity by Oft, Martin, Ratti, Navneet, Vivona, Sandro, Emmerich, Jan, Riener, Romina, Koliesnik, Ievgen O., McCauley, Scott, Bauer, Michele, Semana, Marie, Rokkam, Deepti, Jayaraman, Bhargavi, Malefyt, Rene de Waal, Aspuria, Paul-Joseph, Totagrande, Michael, Mehta-Damani, Anita, Lupardus, Patrick J., Kastelein, Rob A.

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: